Drug Disposition Analysis
Drug Disposition Analysis - Related Videos
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
0 Views •
Cited by 48 •
2015
Here we describe a technique to cannulate the mesenteric lymph duct in rats which enables quantification of lipid and drug transport via the lymphatic system following intestinal delivery. The technique can be adapted to assess mesenteric lymph concentrations and/or transport of fluid, immune cells, peptides, proteins and lipophilic molecules.
01:26
Therapeutic Drug Monitoring: Drug Analysis Methods
0 Views •
2025
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
15:41
Improved Visualization and Quantitative Analysis of Drug Effects Using Micropatterned Cells
0 Views •
Cited by 14 •
2010
Adhesive micropatterns that normalize cellular architecture can be used to increase sensitivity in the detection of drug effects, improve reproducibility and simplify automated image acquisition and analysis. Such technology will benefit drug/siRNA screening assays, performed on conventional cell culture supports and consequently suffering from excessive cell-to-cell variability.
07:48
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
0 Views •
Cited by 1 •
2015
Receptor trafficking modulates signaling and cell responsiveness to ligands and is, itself, responsive to cell conditions, including ligand-induced signaling. Here, we describe a powerful and flexible technique for quantitatively assessing drug-induced receptor trafficking using immunolabeling and colocalizational analysis.
06:14
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
0 Views •
Cited by 18 •
2017
Ivacaftor and ivacaftor-lumacaftor combination are two new CF drugs. However, there is still a dearth of understanding on their PK/PD and pharmacology. We present an optimized HPLC-MS technique for the simultaneous analysis of ivacaftor and its major metabolites, and lumacaftor.
FAQs
These measures describe different dimensions of exposure rather than interchangeable results. Clearance reflects how efficiently drug leaves the body, volume of distribution characterizes its apparent distribution, bioavailability indicates the fraction reaching systemic circulation, and half-life summarizes the time course of decline. Considering them together helps investigators judge whether a regimen can produce effective exposure without excessive exposure.
Sampling drug concentrations over time allows investigators to connect observed exposure with the underlying disposition phases. Changes in the concentration-time profile can be evaluated in relation to absorption, distribution, metabolism, and excretion, while calculated pharmacokinetic measures summarize those patterns. This time-based view is essential for comparing how a drug behaves under different conditions or in different patients.
Patient variability matters because the same administered regimen may not produce the same concentration profile in every individual. Disposition analysis can reveal differences in exposure that affect whether concentrations remain therapeutically useful or become excessive. It also helps identify potential drug interactions by showing when another treatment may be associated with altered drug disposition and changed pharmacokinetic measures.
An analysis begins by relating drug concentrations in biological samples to their collection times. Investigators then calculate measures such as clearance, volume of distribution, bioavailability, and half-life, and interpret the results in the context of the administered dose and clinical objective. This workflow turns concentration data into evidence for comparing regimens and evaluating exposure.
Comparing formulations or routes of administration focuses attention on differences in bioavailability and resulting concentration-time profiles. Drug Disposition Analysis can show whether alternative delivery approaches produce different exposure, which supports formulation selection and evaluation of how a route influences clinical use. The comparison is quantitative because it relies on measured concentrations and derived pharmacokinetic measures.
Clinical researchers apply the results to select doses that balance therapeutic exposure with safety. The same analyses can support individualized therapy by identifying patient-specific differences in disposition and by indicating whether a candidate drug reaches effective concentrations without excessive exposure. Thus, the findings inform decisions from candidate evaluation through clinical regimen design.